Life sciences company
VolitionRx is engaged in the development of blood-based diagnostic tests for
different types of cancer. Demonstrating significant headway with its NuQ®
assays, VolitionRx recently released data from a pilot study of the test to
diagnose prostate cancer.
Results from the trial show
that NuQ assays were able to detect roughly 80 percent of prostate cancer cases
and also has the ability to differentiate between colorectal and prostate
cancer.
As VolitionRx continues to
develop its NuQ tests, it’s impossible to ignore the global need for such
technology and the value of the company’s ongoing research and development
initiatives.
More than 1.1 million cases
of prostate cancer were recorded in 2012, accounting for approximately 8
percent of all new cancer cases and 15 percent of cancer in men, according to
the latest figures from the World Cancer Research Fund International.
Furthermore, prostate cancer
is the most frequently diagnoses non-skin cancer in the United States, and the
third leading cause of cancer deaths in the nation, reports the National
Institutes of Health (NIH). An NIH online report entitled “The Worldwide
Epidemiology of Prostate Cancer: Perspectives from Autopsy Studies,” concludes
in recognition of the value of accurate diagnostics.
“The clinical incidence,
mortality, and to a lesser degree prevalence of prostate cancer varies among
various geographical regions of the world. The approach to screening, early
detection initiatives, and availability of treatment modalities has a major
impact on disease epidemiology.”
By detecting two major
cancers with a blood test, VolitionRx has not only achieved an important
company milestone, but has also warranted further investigation for panels of
its NuQ tests as a cancer diagnostic tool.
For more information, visit
www.volitionrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
